Consensus $17.55M. “Personalis (PSNL) championed a defining year in 2025 demonstrating that our Win-in-MRD strategy is working,” said Chris Hall, CEO and president. “While we entered the year with an ambitious goal to grow clinical volumes by 30% to 40% sequentially through the year, we ultimately surpassed those targets with nearly 400% clinical volume growth over last year. This exponential growth, culminating in over 16,000 tests, proves that oncologists are increasingly demanding the ultrasensitivity that NeXT Personal has pioneered.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSNL:
- TEM, KDK, PSNL: Cathie Wood Loads Up on AI Health Tech, Trims SHOP & ROKU
- Personalis assumed with an Equal Weight at Morgan Stanley
- Personalis Announces $100M Stock Offering Amendment
- Personalis Sees Revised Reimbursement Rates for Cancer Tests
- Personalis price target raised to $9 from $5 at Morgan Stanley